[{"id":"b86a46ce-9239-437b-8205-8587adbd65e1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00357448","created_at":"2021-01-18T01:14:18.217Z","updated_at":"2024-07-02T16:36:59.620Z","phase":"Phase 1","brief_title":"Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer","source_id_and_acronym":"NCT00357448","lead_sponsor":"University of Washington","biomarkers":" IL6 • TNFA • IL2 • IL10 • TGFB1 • TGFB2","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL2 • IL10 • TGFB1 • TGFB2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ontak (denileukin diftitox)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2005","start_date":" 04/01/2005","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":"","study_completion_date":"","last_update_posted":"2019-05-14"}]